Immunotherapy cocktail shows promise in shrinking esophageal tumors before surgery
NCT ID NCT04974047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding the immunotherapy drug tislelizumab to chemotherapy and/or radiation before surgery could help completely eliminate esophageal cancer in 70 patients. The goal was to see if the tumor and all cancer cells in lymph nodes were gone at the time of surgery. The study also tracked how many patients had clean surgical margins and how long they stayed cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug) combined with chemotherapy (paclitaxel, cisplatin, 5-fluorouracil) and/or radiation
What this could lead to
If successful, this approach could increase the chance of completely removing esophageal cancer before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial (70 people) with no control group, so results may not be definitive. Side effects from the drug combination and radiation can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Anhui Provincial Hospital
Hefei, Anhui, 230000, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
-
Tangdu Hospital
Xi'an, Shaanxi, 710038, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China